This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
tim.hodson Wed, 04/09/2025 - 14:38 April 9, 2025 Idorsia Ltd recently announced that the US Food & Drug Administration (FDA), after having released Tryvio from its REMS (Risk Evaluation and Mitigation Strategy) requirement ( announced March 17, 2025 ), has now approved the updated label for Tryvio(aprocitentan). Hypertension.
tim.hodson Wed, 01/08/2025 - 14:11 Jan. 8, 2025 Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidneydisease (CKD) and other diseases, hasannounced that the U.S.
Circulation, Volume 151, Issue 10 , Page 716-732, March 11, 2025. Albuminuriaincreased urine albumin excretionis associated with cardiovascular mortality among patients with diabetes, hypertension, chronic kidneydisease, or heart failure, as well as among adults with few cardiovascular risk factors.
Hypertension, Volume 82, Issue 1 , Page 14-25, January 1, 2025. Podocyte dysfunction, resulting from oxidative stress, dysregulated prosurvival signaling, or structural damage, can drive the development of proteinuria and glomerulosclerosis in hypertensive nephropathy.
Stroke, Volume 56, Issue Suppl_1 , Page ADP60-ADP60, February 1, 2025. Background:Chronic kidneydisease (CKD) has emerged as an independent risk factor for cerebral microhemorrhages (CMH). adenine diet to induce CKD, or angiotensin II (ATII) via subcutaneous osmotic pumps to induce HTN and compared with control mice.
On-demand access is available now and will remain open until December 2025. If you attended the 19th Annual Cardiometabolic Health Congress (CMHC), please reach out to info@cardiometabolichealth.org and we will provide you with a complimentary access code to this activity. When Will It Be Available?
Stroke, Volume 56, Issue Suppl_1 , Page AWP294-AWP294, February 1, 2025. Background:Racial disparities have been well described in cardiovascular disease. Patients were categorized into two groups, one with Black or African American and another with White race patients. Both groups were followed for 12 months.
Stroke, Volume 56, Issue Suppl_1 , Page A49-A49, February 1, 2025. Hypertension, diabetes, hyperlipidemia, and chronic kidneydisease are well-known cardiovascular risk factors for ICH. Introduction:Intracranial hemorrhage (ICH) is the most severe adverse effect of anticoagulation in atrial fibrillation (AF) patients.
tim.hodson Wed, 03/26/2025 - 14:25 March 17, 2025 Bayer recently announcedthat the U.S. 2 Most are balancing multiple comorbidities, such as obesity, diabetes, hypertension and chronic kidneydisease (CKD). Accessed February 21, 2025. Accessed March 5, 2025. Accessed February 21, 2025.
milla1cf Fri, 06/28/2024 - 19:07 June 28, 2024 — AstraZeneca has set out a new ambition for Healthy Heart Africa , its flagship health equity initiative, to target a broader range of non-communicable diseases (NCDs), including chronic kidneydisease (CKD) as well as hypertension and cardiovascular disease.
Stroke, Volume 56, Issue Suppl_1 , Page ADP47-ADP47, February 1, 2025. Introduction:Chronic kidneydisease (CKD) is a risk factor for intracerebral hemorrhage (ICH) and for worse outcomes following ICH.
Stroke, Volume 56, Issue Suppl_1 , Page AWP319-AWP319, February 1, 2025. Reliability of self-reported risk factors was high in overweight (F1 0.81) and diabetes (F1 0.71), moderate in hearing impairment (F1 0.59) and hypertension (F1 0.56) and low in hypercholesterolemia (F1 0.49) and kidneydisease (F1 0.25).
Stroke, Volume 56, Issue Suppl_1 , Page A102-A102, February 1, 2025. Background and Purpose:Chronic kidneydisease (CKD) is associated with an increased risk of stroke and worse outcomes, yet it is often asymptomatic, with an estimated 90% of individuals unaware they have CKD until its later stages. female, 22.1%
Stroke, Volume 56, Issue Suppl_1 , Page AWP184-AWP184, February 1, 2025. Objective:High calcium (Ca), low phosphate(P), and Ca-P product (CPP) levels are associated with cardiovascular disease and coronary artery atherosclerosis in patients with chronic kidneydisease.
Stroke, Volume 56, Issue Suppl_1 , Page AWP301-AWP301, February 1, 2025. VRFs included hypertension, diabetes, kidneydisease, smoking, drug or alcohol abuse, antithrombotic medication use, and sleep apnea. Introduction:While intracranial hemorrhage (ICH) is uncommon in young adults (18-55), its incidence is on the rise.
Written by Jesse McLaren An 80 year old patient with diabetes/hypertension/ cirrhosis had a recent increase in candesartan for their hypertension, and was also on spirolactone and nadolol. Acute hyperkalemia in the emergency department: a summary from a KidneyDisease: Improving Global Outcomes conference. References 1.
Cardiovascular disease remains the leading cause of death worldwide , claiming 18 million lives annually. 42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues. In the U.S., Click here to start: Join the Cardiometabolic Health Congress in Boston in 2024.
Mechanical complications such as free wall rupture, VSR and papillary muscle rupture is more likely to occur in patients who are older, female, hypertensive, have chronic kidneydisease, and have no prior history of smoking. The patient was not considered a surgical candidate. 2018, July 30). American College of Cardiology.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content